Interventional Oncology Market Size, Share, Trends, Growth Outlook

Interventional Oncology Market is estimated to increase at a Compounded Annual Growth Rate of 7.3% CAGR over the forecast period from 2024 to 2030

The Interventional Oncology Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Product ( Embolization Devices, Ablation Devices, Support Devices), By Procedure (Thermal Tumor Ablation, Non-Thermal Tumor Ablation, Transcatheter Arterial Chemoembolization, Transcatheter Arterial Radioembolizatio, Transcatheter Arterial Embolization), By Disease (Liver Cancer, Lung Cancer, Bone Metastasis, Kidney Cancer, Breast Cancer, Prostate Cancer, Others), By End-User (Hospitals, Ambulatory Surgery Centers, Research & Academic Institutes).

An Introduction to Interventional Oncology Market in 2024

Interventional oncology encompasses minimally invasive procedures that utilize imaging guidance and interventional techniques to diagnose, treat, and manage cancerous tumors. In 2024, interventional oncology continues to transform cancer care by offering alternatives to traditional surgery, chemotherapy, and radiation therapy for select patients. Interventional radiologists and oncologists perform a range of procedures, including tumor embolization, radiofrequency ablation (RFA), microwave ablation, cryoablation, and transarterial chemoembolization (TACE), to target and destroy tumors while minimizing damage to surrounding healthy tissues. Additionally, advancements in imaging modalities, such as cone-beam computed tomography (CBCT) and magnetic resonance imaging (MRI), enable real-time visualization of tumors and precise delivery of therapeutic agents, improving treatment accuracy and outcomes. As the field of interventional oncology evolves, multidisciplinary collaborations and patient-centered approaches drive innovation in minimally invasive cancer therapies, expanding treatment options and improving quality of life for cancer patients.

Market Trend: Shift Towards Minimally Invasive Procedures

A prominent trend in the interventional oncology market is the increasing adoption of minimally invasive procedures for cancer treatment. As patients seek less invasive alternatives to traditional surgery, and as advancements in technology and techniques continue to improve, interventional oncology procedures such as radiofrequency ablation (RFA), microwave ablation, cryoablation, and transarterial chemoembolization (TACE) are becoming increasingly popular. These procedures offer benefits such as reduced recovery times, fewer complications, and improved quality of life for patients, driving a shift towards minimally invasive approaches in the treatment of various cancers including liver, lung, kidney, and bone metastases. This trend reflects the growing recognition of interventional oncology as a valuable component of comprehensive cancer care, offering less invasive options for patients who may not be suitable candidates for surgery or systemic therapies.

Market Driver: Increasing Incidence of Cancer and Demand for Alternative Therapies

A key driver propelling the interventional oncology market is the increasing incidence of cancer worldwide and the growing demand for alternative treatment modalities that offer effective outcomes with fewer side effects. With cancer incidence rates on the rise due to factors such as aging populations, lifestyle changes, and environmental exposures, there is a pressing need for innovative approaches to cancer treatment. Interventional oncology procedures provide minimally invasive alternatives to surgery and systemic therapies, offering targeted, localized treatment options that can be repeated as needed while preserving healthy tissue and organ function. The desire for better treatment outcomes and quality of life, coupled with the need for personalized cancer care, drives the adoption of interventional oncology techniques among healthcare providers and patients alike, fueling market growth in the oncology interventional segment.

Market Opportunity: Development of Advanced Imaging and Navigation Technologies

An opportunity for growth in the interventional oncology market lies in the development of advanced imaging and navigation technologies to enhance procedural accuracy and efficacy. Real-time imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and cone-beam CT (CBCT) play a crucial role in guiding interventional oncology procedures, enabling precise targeting of tumors and monitoring of treatment response. Additionally, the integration of advanced navigation systems, image fusion techniques, and augmented reality platforms enhances procedural planning, visualization, and navigation during interventional oncology procedures, improving outcomes and patient safety. By investing in the development and commercialization of innovative imaging and navigation technologies, manufacturers and healthcare providers can further enhance the capabilities of interventional oncology procedures, expand their applications to new cancer types and patient populations, and ultimately improve patient care in the fight against cancer.

Interventional Oncology Market Share Analysis: Radioembolic Agents in Liver Cancer Treatment is the fastest growing segment over the forecast period to 2030

The Radioembolic Agents segment within the Interventional Oncology Market is experiencing the most rapid growth, particularly in the treatment of liver cancer, and several factors contribute to this trend. Firstly, liver cancer, including hepatocellular carcinoma (HCC) and metastatic liver tumors, poses a significant global health burden, with limited treatment options and poor prognosis for advanced-stage disease. Radioembolization, also known as selective internal radiation therapy (SIRT), involves the intra-arterial delivery of radioactive microspheres directly into the blood vessels supplying the tumor, leading to localized radiation-induced tumor destruction while sparing healthy liver tissue. This targeted approach offers several advantages, including enhanced tumor response rates, prolonged survival, and improved quality of life for patients with inoperable liver tumors. Additionally, advancements in radioembolic agents, such as improved microsphere design, radioisotope selection (e.g., Yttrium-90), and delivery techniques, have optimized treatment efficacy and safety profiles, leading to increased adoption by interventional oncologists and hepatologists worldwide. Moreover, clinical evidence and real-world data have demonstrated the effectiveness of radioembolization in managing liver cancer, including both primary and metastatic lesions, across various stages of the disease continuum. Furthermore, the expanding indications for radioembolization, including salvage therapy after failed systemic treatments, downstaging of tumors for potential surgical resection or transplantation, and palliative care in advanced-stage disease, have contributed to its growing utilization in clinical practice. Overall, the Radioembolic Agents segment in liver cancer treatment is experiencing rapid growth due to its targeted therapeutic approach, technological advancements, clinical efficacy, and expanding treatment indications, highlighting its importance in the multidisciplinary management of liver cancer.

Interventional Oncology Competitive Analysis

The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossABK Biomedical Inc, Accuray Inc, Alpinion Medical Systems Co. Ltd, AngioDynamics Inc, Baylis Medical Company Inc, Becton, Dickinson and Company, Boston Scientific Corp, Cook Medical LLC, Endo Shape Inc, Guerbet SA, HealthTronics Inc, IceCure Medical Ltd, IMBiotechnologies Ltd, Instylla Inc, Interface Biomaterials B.V., Johnson & Johnson, Medtronic Inc, MedWaves Inc, Merit Medical Systems Inc, Mermaid Medical A/S, Monteris Medical Inc, Profound Medical corp, Sanarus Medical Inc, Shape Memory Medical Inc, Sirtex Medical Ltd, Teleflex Inc, Terumo Corp, Trisalus Lifesciences Corp, Trod Medical Ltd

Interventional Oncology Market Segmentation

By Product
Embolization Devices
-Radioembolic Agents
-Non-Radio embolic Agents
Ablation Devices
-Radiofrequency (RF) Ablation Devices
-Microwave Ablation Devices
-Cryoablation Devices
-Others
Support Devices
-Microcatheters
-Guidewires
By Procedure
Thermal Tumor Ablation
Non-Thermal Tumor Ablation
Transcatheter Arterial Chemoembolization
Transcatheter Arterial Radioembolizatio
Transcatheter Arterial Embolization
By Disease
Liver Cancer
Lung Cancer
Bone Metastasis
Kidney Cancer
Breast Cancer
Prostate Cancer
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Research & Academic Institutes
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Interventional Oncology Market Companies

ABK Biomedical Inc
Accuray Inc
Alpinion Medical Systems Co. Ltd
AngioDynamics Inc
Baylis Medical Company Inc
Becton, Dickinson and Company
Boston Scientific Corp
Cook Medical LLC
Endo Shape Inc
Guerbet SA
HealthTronics Inc
IceCure Medical Ltd
IMBiotechnologies Ltd
Instylla Inc
Interface Biomaterials B.V.
Johnson & Johnson
Medtronic Inc
MedWaves Inc
Merit Medical Systems Inc
Mermaid Medical A/S
Monteris Medical Inc
Profound Medical corp
Sanarus Medical Inc
Shape Memory Medical Inc
Sirtex Medical Ltd
Teleflex Inc
Terumo Corp
Trisalus Lifesciences Corp
Trod Medical Ltd

Reasons to Buy the Interventional Oncology Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Interventional Oncology Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Interventional Oncology Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Interventional Oncology Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Interventional Oncology Market Size Outlook, $ Million, 2021 to 2030
3.2 Interventional Oncology Market Outlook by Type, $ Million, 2021 to 2030
3.3 Interventional Oncology Market Outlook by Product, $ Million, 2021 to 2030
3.4 Interventional Oncology Market Outlook by Application, $ Million, 2021 to 2030
3.5 Interventional Oncology Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Interventional Oncology Industry
4.2 Key Market Trends in Interventional Oncology Industry
4.3 Potential Opportunities in Interventional Oncology Industry
4.4 Key Challenges in Interventional Oncology Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Interventional Oncology Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Interventional Oncology Market Outlook by Segments
7.1 Interventional Oncology Market Outlook by Segments, $ Million, 2021- 2030
By Product
Embolization Devices
-Radioembolic Agents
-Non-Radio embolic Agents
Ablation Devices
-Radiofrequency (RF) Ablation Devices
-Microwave Ablation Devices
-Cryoablation Devices
-Others
Support Devices
-Microcatheters
-Guidewires
By Procedure
Thermal Tumor Ablation
Non-Thermal Tumor Ablation
Transcatheter Arterial Chemoembolization
Transcatheter Arterial Radioembolizatio
Transcatheter Arterial Embolization
By Disease
Liver Cancer
Lung Cancer
Bone Metastasis
Kidney Cancer
Breast Cancer
Prostate Cancer
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Research & Academic Institutes

8 North America Interventional Oncology Market Analysis and Outlook To 2030
8.1 Introduction to North America Interventional Oncology Markets in 2024
8.2 North America Interventional Oncology Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Interventional Oncology Market size Outlook by Segments, 2021-2030
By Product
Embolization Devices
-Radioembolic Agents
-Non-Radio embolic Agents
Ablation Devices
-Radiofrequency (RF) Ablation Devices
-Microwave Ablation Devices
-Cryoablation Devices
-Others
Support Devices
-Microcatheters
-Guidewires
By Procedure
Thermal Tumor Ablation
Non-Thermal Tumor Ablation
Transcatheter Arterial Chemoembolization
Transcatheter Arterial Radioembolizatio
Transcatheter Arterial Embolization
By Disease
Liver Cancer
Lung Cancer
Bone Metastasis
Kidney Cancer
Breast Cancer
Prostate Cancer
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Research & Academic Institutes

9 Europe Interventional Oncology Market Analysis and Outlook To 2030
9.1 Introduction to Europe Interventional Oncology Markets in 2024
9.2 Europe Interventional Oncology Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Interventional Oncology Market Size Outlook by Segments, 2021-2030
By Product
Embolization Devices
-Radioembolic Agents
-Non-Radio embolic Agents
Ablation Devices
-Radiofrequency (RF) Ablation Devices
-Microwave Ablation Devices
-Cryoablation Devices
-Others
Support Devices
-Microcatheters
-Guidewires
By Procedure
Thermal Tumor Ablation
Non-Thermal Tumor Ablation
Transcatheter Arterial Chemoembolization
Transcatheter Arterial Radioembolizatio
Transcatheter Arterial Embolization
By Disease
Liver Cancer
Lung Cancer
Bone Metastasis
Kidney Cancer
Breast Cancer
Prostate Cancer
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Research & Academic Institutes

10 Asia Pacific Interventional Oncology Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Interventional Oncology Markets in 2024
10.2 Asia Pacific Interventional Oncology Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Interventional Oncology Market size Outlook by Segments, 2021-2030
By Product
Embolization Devices
-Radioembolic Agents
-Non-Radio embolic Agents
Ablation Devices
-Radiofrequency (RF) Ablation Devices
-Microwave Ablation Devices
-Cryoablation Devices
-Others
Support Devices
-Microcatheters
-Guidewires
By Procedure
Thermal Tumor Ablation
Non-Thermal Tumor Ablation
Transcatheter Arterial Chemoembolization
Transcatheter Arterial Radioembolizatio
Transcatheter Arterial Embolization
By Disease
Liver Cancer
Lung Cancer
Bone Metastasis
Kidney Cancer
Breast Cancer
Prostate Cancer
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Research & Academic Institutes

11 South America Interventional Oncology Market Analysis and Outlook To 2030
11.1 Introduction to South America Interventional Oncology Markets in 2024
11.2 South America Interventional Oncology Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Interventional Oncology Market size Outlook by Segments, 2021-2030
By Product
Embolization Devices
-Radioembolic Agents
-Non-Radio embolic Agents
Ablation Devices
-Radiofrequency (RF) Ablation Devices
-Microwave Ablation Devices
-Cryoablation Devices
-Others
Support Devices
-Microcatheters
-Guidewires
By Procedure
Thermal Tumor Ablation
Non-Thermal Tumor Ablation
Transcatheter Arterial Chemoembolization
Transcatheter Arterial Radioembolizatio
Transcatheter Arterial Embolization
By Disease
Liver Cancer
Lung Cancer
Bone Metastasis
Kidney Cancer
Breast Cancer
Prostate Cancer
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Research & Academic Institutes
12 Middle East and Africa Interventional Oncology Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Interventional Oncology Markets in 2024
12.2 Middle East and Africa Interventional Oncology Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Interventional Oncology Market size Outlook by Segments, 2021-2030
By Product
Embolization Devices
-Radioembolic Agents
-Non-Radio embolic Agents
Ablation Devices
-Radiofrequency (RF) Ablation Devices
-Microwave Ablation Devices
-Cryoablation Devices
-Others
Support Devices
-Microcatheters
-Guidewires
By Procedure
Thermal Tumor Ablation
Non-Thermal Tumor Ablation
Transcatheter Arterial Chemoembolization
Transcatheter Arterial Radioembolizatio
Transcatheter Arterial Embolization
By Disease
Liver Cancer
Lung Cancer
Bone Metastasis
Kidney Cancer
Breast Cancer
Prostate Cancer
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Research & Academic Institutes

13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
ABK Biomedical Inc
Accuray Inc
Alpinion Medical Systems Co. Ltd
AngioDynamics Inc
Baylis Medical Company Inc
Becton, Dickinson and Company
Boston Scientific Corp
Cook Medical LLC
Endo Shape Inc
Guerbet SA
HealthTronics Inc
IceCure Medical Ltd
IMBiotechnologies Ltd
Instylla Inc
Interface Biomaterials B.V.
Johnson & Johnson
Medtronic Inc
MedWaves Inc
Merit Medical Systems Inc
Mermaid Medical A/S
Monteris Medical Inc
Profound Medical corp
Sanarus Medical Inc
Shape Memory Medical Inc
Sirtex Medical Ltd
Teleflex Inc
Terumo Corp
Trisalus Lifesciences Corp
Trod Medical Ltd

14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Product
Embolization Devices
-Radioembolic Agents
-Non-Radio embolic Agents
Ablation Devices
-Radiofrequency (RF) Ablation Devices
-Microwave Ablation Devices
-Cryoablation Devices
-Others
Support Devices
-Microcatheters
-Guidewires
By Procedure
Thermal Tumor Ablation
Non-Thermal Tumor Ablation
Transcatheter Arterial Chemoembolization
Transcatheter Arterial Radioembolizatio
Transcatheter Arterial Embolization
By Disease
Liver Cancer
Lung Cancer
Bone Metastasis
Kidney Cancer
Breast Cancer
Prostate Cancer
Others
By End-User
Hospitals
Ambulatory Surgery Centers
Research & Academic Institutes
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)